A Phase II Study of Fruquintinib Combined With Capecitabine as First-line Treatment for Advanced Metastatic Colorectal Cancer Unsuitable for Intravenous Chemotherapy
This is a single center, open-labeled, single arm phase II study aimed to investigate the efficacy and safety of fruquintinib combined with capecitabine as first-line treatment for advanced metastatic colorectal cancer patients unsuitable for intravenous chemotherapy.
Unresectable Metastatic Colorectal Cancer
DRUG: fruquintinib plus capecitabine
Objective Response Rate (ORR), ORR according to Response Evaluation Criteria in Solid Tumors (RECIST) version. 1.1, From Baseline to primary completion date, about 3 years
Overall Survival (OS), OS is determined from the date of treatment to death from any cause or the last follow-up date, From Baseline to primary completion date, about 3 years|Progression Free Survival (PFS), PFS is determined from the date of treatment to PD or death from any cause, From Baseline to primary completion date, about 3 years|Disease Control Rate (DCR), DCR according to Response Evaluation Criteria in Solid Tumors (RECIST) version. 1.1, From Baseline to primary completion date, about 3 years|Adverse Events and Serious Adverse Events, Safety and tolerance will be evaluated by incidence, severity and outcomes of adverse events (AEs) and categorized by severity in accordance with the NCI CTC AE Version 5.0., From Baseline to primary completion date, about 3 years|Quality of Life (QoL), Quality of life is assessed using the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) C30. It will be evaluated at Screening, Tumor Assessment Visit and End of Treatment visit., From Baseline to primary completion date, about 3 years
Fruquintinib is an oral small molecule inhibitor of VEGFR1/2/3, this phase II study aimed to investigate the efficacy and safety of fruquintinib combined with capecitabine as first-line treatment for advanced metastatic colorectal cancer patients of elderly or those unsuitable for intravenous chemotherapy.